News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
607,141 Results
Type
Article (25691)
Company Profile (218)
Press Release (581226)
Multimedia
Podcasts (122)
Webinars (10)
Section
Business (194753)
Career Advice (546)
Deals (29750)
Drug Delivery (101)
Drug Development (75014)
Employer Resources (48)
FDA (14176)
Job Trends (11143)
News (291942)
Policy (23958)
Tag
2027 BioCapital Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (7)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (1)
2027 Genetown Standard (6)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (6)
Academia (1460)
Academic (1)
Accelerated approval (64)
ADA (42)
Adcomms (29)
Allergies (150)
Alliances (41476)
ALS (226)
Alzheimer's disease (1705)
Antibody-drug conjugate (ADC) (574)
Approvals (14757)
Artificial intelligence (610)
ASCO (302)
Autoimmune disease (394)
Automation (49)
Bankruptcy (300)
Belgium (4)
Best Places to Work (9130)
BIO (67)
Biologics (12)
BIOSECURE Act (13)
Biosimilars (204)
BioSpace Insights (78)
Biotechnology (147)
Bladder cancer (214)
Brain cancer (87)
Breast cancer (840)
Cancer (6539)
Cardiovascular disease (511)
Career advice (465)
Career pathing (7)
CAR-T (419)
CDC (12)
CDMO (110)
Celiac Disease (3)
Cell therapy (1141)
Cervical cancer (48)
Clinical research (67478)
Collaboration (2180)
Commercialization (7)
Company closure (6)
Compensation (1601)
Complete response letters (86)
COVID-19 (1561)
CRISPR (128)
C-suite (1241)
Cystic fibrosis (165)
Data (8814)
Decentralized trials (1)
Denatured (19)
Depression (188)
Dermatology (106)
Diabetes (628)
Diagnostics (5232)
Digital health (53)
Diversity (5)
Diversity, equity & inclusion (12)
Drug discovery (325)
Drug pricing (107)
Drug shortages (26)
Duchenne muscular dystrophy (341)
Earnings (81044)
Editorial (35)
Employer branding (6)
Employer resources (45)
Events (105620)
Executive appointments (1020)
FDA (18224)
Fibrodysplasia Ossificans Progressiva (9)
Fragile X (1)
Friedreich's ataxia (25)
Frontotemporal dementia (33)
Funding (1726)
Gene editing (274)
Generative AI (47)
Gene therapy (909)
GLP-1 (870)
Government (2311)
Grass and pollen (2)
Guidances (369)
Healthcare (13631)
Hematology (174)
HIV (91)
Huntington's disease (69)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (120)
Immunology and inflammation (304)
Immuno-oncology (121)
Indications (229)
Infectious disease (1840)
Inflammatory bowel disease (224)
Inflation Reduction Act (7)
Influenza (105)
Intellectual property (311)
Interviews (82)
IPO (14257)
IRA (23)
Job creations (2419)
Job search strategy (418)
JPM (47)
Kidney cancer (21)
Labor market (27)
Layoffs (323)
Leadership (10)
Legal (5860)
Licensing (24)
Liver cancer (90)
Longevity (35)
Lung cancer (917)
Lymphoma (500)
Machine learning (48)
Management (12)
Manufacturing (1056)
Marketing (12)
MASH (217)
Medical affairs (2)
Medical device (10820)
Medtech (11022)
Mergers & acquisitions (16743)
Metabolic disorders (1545)
mRNA (195)
Multiple sclerosis (193)
NASH (15)
Netherlands (2)
Neurodegenerative disease (491)
Neuropsychiatric disorders (115)
Neuroscience (3370)
Neurotech (1)
NextGen: Class of 2026 (4450)
Non-profit (2311)
Now hiring (18)
Obesity (679)
Opinion (187)
Ovarian cancer (244)
Pain (279)
Pancreatic cancer (349)
Parkinson's disease (386)
Partnered (28)
Patents (632)
Patient advocacy (1)
Patient recruitment (866)
Patient selection (1)
Peanut (50)
People (49359)
Peptides (5)
Pharmaceutical (40)
Pharmacy benefit managers (18)
Phase 1 (21260)
Phase 2 (29904)
Phase 3 (21835)
Pipeline (10841)
Policy (186)
Postmarket research (2327)
Preclinical (8807)
Press Release (63)
Prostate cancer (346)
Psychedelics (81)
Radiopharmaceuticals (359)
Rare diseases (1314)
Real estate (4010)
Recruiting (22)
Regenerative medicine (1)
Regulatory (21403)
Reports (32)
Research institute (1683)
Resumes & cover letters (75)
Rett syndrome (52)
RNA editing (26)
RSV (61)
Schizophrenia (173)
Series A (308)
Series B (218)
Service/supplier (5)
Sickle cell disease (127)
Special edition (18)
Spinal muscular atrophy (178)
Sponsored (35)
Startups (2887)
Stomach cancer (16)
Supply chain (99)
Tariffs (39)
The Weekly (101)
Vaccines (640)
Venture capital (91)
Weight loss (400)
Women's health (116)
Worklife (2)
Date
Today (128)
Last 7 days (589)
Last 30 days (2082)
Last 365 days (27537)
2026 (19464)
2025 (27178)
2024 (31205)
2023 (34832)
2022 (44560)
2021 (47349)
2020 (43224)
2019 (32739)
2018 (24429)
2017 (25118)
2016 (23874)
2015 (29969)
2014 (25498)
2013 (21270)
2012 (23311)
2011 (23528)
2010 (23009)
Location
Africa (376)
Alabama (94)
Alaska (4)
Arizona (373)
Arkansas (14)
Asia (29369)
Australia (4485)
California (14254)
Canada (3769)
China (1523)
Colorado (596)
Connecticut (575)
Delaware (374)
Europe (58833)
Florida (2151)
Georgia (462)
Hawaii (4)
Idaho (52)
Illinois (1019)
India (108)
Indiana (520)
Iowa (22)
Japan (607)
Kansas (127)
Kentucky (47)
Louisiana (53)
Maine (31)
Maryland (1564)
Massachusetts (10337)
Michigan (343)
Minnesota (696)
Mississippi (5)
Missouri (151)
Montana (27)
Nebraska (14)
Nevada (135)
New Hampshire (73)
New Jersey (3686)
New Mexico (25)
New York (3704)
North Carolina (1769)
North Dakota (11)
Northern California (7274)
Ohio (384)
Oklahoma (18)
Oregon (34)
Pennsylvania (2766)
Puerto Rico (26)
Rhode Island (41)
South America (561)
South Carolina (83)
South Dakota (1)
Southern California (5732)
Tennessee (179)
Texas (2369)
United States (49408)
Utah (417)
Vermont (1)
Virginia (280)
Washington D.C. (56)
Washington State (1143)
West Virginia (3)
Wisconsin (131)
Wyoming (1)
607,141 Results for "vital therapies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Senphonix Receives National Science Foundation Grant to Advance SleeveSense, a Continuous, Long-Term Vitals Monitoring Platform
September 10, 2026
·
5 min read
Press Releases
Albert Einstein College of Medicine Launches BIO-VITAL to Accelerate Gerotherapeutics
June 10, 2026
·
4 min read
Opinion
Assessing shared failures with AI is key to cell and gene therapy’s evolution
If we guard our secrets, patients suffer. Only through a commitment to transparency and data sharing—and artificial intelligence—can we make cell and gene therapies safer and more effective.
August 18, 2026
·
5 min read
·
Alexander Seyf
Opinion
Blood centers can help biopharma scale cell and gene therapies
Blood centers have the donors, resources and community footprint drug sponsors need to solve supply chain issues around cell and gene therapies.
September 15, 2026
·
6 min read
·
Becky Cap
Funding
Encoded raises $275M series F for Dravet syndrome gene therapy
Encoded Therapeutics’ lead asset ETX101 is a gene therapy being tested for Dravet syndrome. Phase 1/2 data showed substantial reductions in seizures.
September 10, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
BMS ends Cellares pact over cell therapy production problems, triggering layoffs
Setbacks to efforts to use Cellares’ automated platform to make an approved CAR-T cell therapy led BMS to terminate its partnership with the manufacturing specialist.
August 26, 2026
·
2 min read
·
Nick Paul Taylor
Manufacturing
FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
ITM Isotope Technologies plans on resubmitting its advanced cancer radiopharma therapy to the FDA after addressing the agency’s concerns.
August 11, 2026
·
1 min read
·
Gabrielle Masson
Approvals
FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease
Zanvastro, an antisense oligonucleotide therapy, represents the first independent neurology launch for Ionis Pharmaceuticals, which intends to leverage the foothold for more approvals in rare neurodegenerative diseases, including Angelman syndrome.
September 3, 2026
·
5 min read
·
Heather McKenzie
Press Releases
Incentive scheme for rare disease drug development vital for sector, says leading biotech
January 12, 2026
·
1 min read
Press Releases
Mercury Medical Awarded Respiratory Therapy, Resuscitation Devices Agreement with Premier, Inc.
July 22, 2026
·
2 min read
1 of 60,715
Next